Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 June, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Pfizer Ltd

Basic Stock Data

Last Updated: June 20, 2024, 10:31 pm

Market Cap 21,937 Cr.
Current Price 4,786
High / Low5,018/3,724
Stock P/E40.2
Book Value 786
Dividend Yield0.73 %
ROCE21.9 %
ROE16.0 %
Face Value 10.0
PEG Ratio25.03

Competitors of Pfizer Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Sequent Scientific Ltd 3,095 Cr. 124156/80.0 26.30.00 %0.90 %2.46 % 2.00
Bacil Pharma Ltd 13.9 Cr. 23.529.2/4.68 2.070.00 %4.94 %5.19 % 10.0
TTK Healthcare Ltd 2,077 Cr. 1,4681,744/1,10133.0 7080.68 %8.67 %6.43 % 10.0
Caplin Point Laboratories Ltd 10,758 Cr. 1,4171,619/78123.5 3050.32 %25.2 %23.0 % 2.00
Krebs Biochemicals & Industries Ltd 157 Cr. 72.894.0/60.0 55.30.00 %10.4 %% 10.0
Industry Average15,210.89 Cr1,169.1038.35189.020.35%17.27%16.72%6.46

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales593535749636676550593637622573531575540
Expenses397409463447481384401406418391421393387
Operating Profit197126286189195165192232203182111183153
OPM %33%24%38%30%29%30%32%36%33%32%21%32%28%
Other Income153712151817-1182132712333644
Interest4422244343333
Depreciation27272727273427262626161518
Profit before tax18013226917518414543415201165126201176
Tax %22%24%26%18%22%13%25%25%25%21%26%26%26%
Net Profit1411012001431441263331115113094149130
EPS in Rs30.8721.9843.7031.2531.4627.507.1268.0032.9328.3420.4432.5628.41

Last Updated: June 10, 2024, 5:12 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 27, 2024, 5:53 am

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales1,0491,1121,8532,0121,9661,9692,0822,1522,2392,6112,4252,193
Expenses8658721,4381,5791,6161,4681,5161,5781,5261,7751,6161,558
Operating Profit184239414433350501566574712836809635
OPM %18%22%22%22%18%25%27%27%32%32%33%29%
Other Income51910944972321141671838163134188
Interest21212121115111315
Depreciation882505863667110310911510662
Profit before tax694340207470517548660642669773824746
Tax %27%35%66%35%35%34%35%21%26%21%24%26%
Net Profit50322170305337360429509498613624551
EPS in Rs168.6274.0115.2666.6773.6278.7193.79111.29108.77133.90136.38120.52
Dividend Payout %19%486%82%22%27%25%24%297%32%26%29%29%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-56.06%-68.33%335.71%10.49%6.82%19.17%18.65%-2.16%23.09%1.79%-11.70%
Change in YoY Net Profit Growth (%)0.00%-12.26%404.04%-325.22%-3.67%12.34%-0.52%-20.81%25.25%-21.30%-13.49%

Growth

Compounded Sales Growth
10 Years:7%
5 Years:1%
3 Years:-1%
TTM:-10%
Compounded Profit Growth
10 Years:10%
5 Years:5%
3 Years:3%
TTM:-9%
Stock Price CAGR
10 Years:13%
5 Years:8%
3 Years:-4%
1 Year:24%
Return on Equity
10 Years:16%
5 Years:18%
3 Years:19%
Last Year:16%

Last Updated: June 16, 2024, 4:59 pm

Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital30303046464646464646464646
Reserves1,2751,6656291,9272,1182,3732,6372,9663,3502,3472,8193,1623,227
Borrowings00022222263394143
Other Liabilities2773653186387228401,0049261,007810997752691
Total Liabilities1,5822,0609772,6142,8883,2613,6903,9404,4053,2663,9014,0014,006
Fixed Assets312620944925902950886973894869749731
CWIP003133151013189
Investments484644433700000000
Other Assets1,5021,9889091,6141,9232,3432,7393,0543,4322,3693,0303,2443,266
Total Assets1,5822,0609772,6142,8883,2613,6903,9404,4053,2663,9014,0014,006

Reserves and Borrowings Chart

Pfizer Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 24-1613211334532933298323427667356
Cash from Investing Activity 27862610368-701-250-238351,530-469-575-36
Cash from Financing Activity -14-43-1,360-1-62-83-110-110-164-1,571-181-346
Net Cash Flow288567-1,125181-417-3-17231,690-1,613-88-26

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow184.00239.00412.00431.00348.00499.00564.00572.00649.00797.00768.00595.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Pfizer Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days474957322620293029182023
Inventory Days186181148191167148147189198199173175
Days Payable13816515616515717824521319713010291
Cash Conversion Cycle9565495836-10-696318791107
Working Capital Days717257-9-46-57-15-713-87
ROCE %23%19%29%24%22%17%21%23%20%23%29%26%

Financial Efficiency Indicators Chart

Pfizer Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%
FIIs1.89%2.07%2.07%2.13%2.20%2.55%2.55%2.77%2.80%2.81%2.82%3.03%
DIIs14.63%15.15%15.15%15.03%15.06%14.83%14.88%14.93%14.89%14.89%15.00%15.15%
Public19.55%18.86%18.86%18.92%18.82%18.70%18.65%18.39%18.38%18.37%18.24%17.87%
No. of Shareholders1,45,9801,21,1531,21,1531,26,8081,25,2871,23,4491,22,0281,17,9501,17,1941,15,9881,16,9481,12,456

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund947,9100.94387.2140,6462024-06-20573.97%
Nippon India Multi Cap Fund362,8480.65148.22140,6462024-06-20157.99%
Aditya Birla Sun Life ELSS Tax Saver Fund334,8740.96136.79140,6462024-06-20138.1%
Nippon India Pharma Fund293,2491.93119.79140,6462024-06-20108.5%
Aditya Birla Sun Life MNC Fund - Div224,3822.6391.66140,6462024-06-2059.54%
Aditya Birla Sun Life MNC Fund - Gr224,3822.6391.66140,6462024-06-2059.54%
SBI Magnum Midcap Fund206,0340.5884.16140,6462024-06-2046.49%
HSBC Midcap Fund155,3000.7263.44140,6462024-06-2010.42%
DSP Equity Opportunities Fund140,6460.657.45140,6462024-06-200%
DSP ELSS Tax Saver Fund112,1090.3645.79140,6462024-06-20-20.29%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)120.51128.50133.89108.77111.28
Diluted EPS (Rs.)120.51136.38133.89108.77111.28
Cash EPS (Rs.)134.12159.44159.03132.68133.85
Book Value[Excl.RevalReserv]/Share (Rs.)785.91701.05626.10523.07742.18
Book Value[Incl.RevalReserv]/Share (Rs.)785.91701.05626.10523.07742.18
Dividend / Share (Rs.)35.0070.0035.0035.00330.00
Revenue From Operations / Share (Rs.)479.38530.00570.71489.30470.31
PBDIT / Share (Rs.)178.32198.89196.37173.38165.37
PBIT / Share (Rs.)164.71175.82171.23149.47142.81
PBT / Share (Rs.)163.07180.11168.94146.17140.43
Net Profit / Share (Rs.)120.51136.38133.89108.77111.29
PBDIT Margin (%)37.1937.5234.4035.4335.16
PBIT Margin (%)34.3533.1730.0030.5430.36
PBT Margin (%)34.0133.9829.6029.8729.86
Net Profit Margin (%)25.1325.7323.4622.2223.66
Return on Networth / Equity (%)15.3319.4521.3820.7914.99
Return on Capital Employeed (%)20.4624.0525.7027.4418.49
Return On Assets (%)13.0315.5915.7015.2311.55
Asset Turnover Ratio (%)0.530.610.720.580.51
Current Ratio (X)5.073.842.812.493.49
Quick Ratio (X)4.273.212.281.923.00
Inventory Turnover Ratio (X)0.780.790.800.770.84
Dividend Payout Ratio (NP) (%)0.0047.6526.13303.3824.37
Dividend Payout Ratio (CP) (%)0.0040.7622.00248.7020.26
Earning Retention Ratio (%)0.0052.3573.87-203.3875.63
Cash Earning Retention Ratio (%)0.0059.2478.00-148.7079.74
Interest Coverage Ratio (X)52.9467.9585.6452.5069.73
Interest Coverage Ratio (Post Tax) (X)36.2645.1359.3933.9347.92
Enterprise Value (Cr.)17140.8213990.3218276.3719572.8116195.40
EV / Net Operating Revenue (X)7.825.777.008.747.53
EV / EBITDA (X)21.0115.3820.3424.6721.41
MarketCap / Net Operating Revenue (X)8.756.547.629.248.56
Retention Ratios (%)0.0052.3473.86-203.3875.62
Price / BV (X)5.344.946.958.645.42
Price / Net Operating Revenue (X)8.756.547.629.248.56
EarningsYield0.020.030.030.020.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 5,092.46

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 6.40% compared to the current price 4786

Intrinsic Value: 5,174.26

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 8.11% compared to the current price ₹4786

Last 5 Year EPS CAGR: 1.61%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.00%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -1.00, which is a positive sign.
  3. The company has higher reserves (2,461.92 cr) compared to borrowings (16.25 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (1.58 cr) and profit (590.83 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 45.50, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pfizer Ltd:
    1. Net Profit Margin: 25.13%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 20.46% (Industry Average ROCE: %)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 15.33% (Industry Average ROE: %)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 36.26
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 4.27
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✗ Stock P/E: 40.2 (Industry average Stock P/E: )
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✗ Total Debt / Equity: N/A
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company

Pfizer Ltd. is a Public Limited Listed company incorporated on 21/11/1950 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24231MH1950PLC008311 and registration number is 008311. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 2610.99 Cr. and Equity Capital is Rs. 45.75 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsThe Capital, 1802 / 1901, 18th Floor, Mumbai Maharashtra 400051contactus.india@pfizer.com
http://www.pfizerindia.com
Management
NamePosition Held
Ms. Meenakshi NevatiaManaging Director
Mr. Milind PatilExecutive Director (Finance) & CFO
Mr. Samir KaziExecutive Director
Mr. Sunil LalbhaiIndependent Director
Mr. Pradip ShahChairman & Ind.Director
Mr. Uday KhannaIndependent Director
Ms. Meena GaneshIndependent Director

FAQ

What is the latest fair value of Pfizer Ltd?

The latest fair value of Pfizer Ltd is ₹5092.46.

What is the Market Cap of Pfizer Ltd?

The Market Cap of Pfizer Ltd is 21,937 Cr..

What is the current Stock Price of Pfizer Ltd as on 21 June 2024?

The current stock price of Pfizer Ltd as on 21 June 2024 is ₹4,786.

What is the High / Low of Pfizer Ltd stocks in FY 2024?

In FY 2024, the High / Low of Pfizer Ltd stocks is 5,018/3,724.

What is the Stock P/E of Pfizer Ltd?

The Stock P/E of Pfizer Ltd is 40.2.

What is the Book Value of Pfizer Ltd?

The Book Value of Pfizer Ltd is 786.

What is the Dividend Yield of Pfizer Ltd?

The Dividend Yield of Pfizer Ltd is 0.73 %.

What is the ROCE of Pfizer Ltd?

The ROCE of Pfizer Ltd is 21.9 %.

What is the ROE of Pfizer Ltd?

The ROE of Pfizer Ltd is 16.0 %.

What is the Face Value of Pfizer Ltd?

The Face Value of Pfizer Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Pfizer Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE